Annexon Biosciences to Participate in Upcoming September Investor Conferences

Rhea-AI Summary

Annexon Biosciences (NASDAQ:ANNX), a biopharmaceutical company focused on developing novel therapies for classical complement-mediated neuroinflammatory diseases, has announced its participation in two major investor conferences in September 2025.

The company's President & CEO Douglas Love will engage in fireside chats at the Wells Fargo Healthcare Conference on September 3 at 3:00 p.m. ET in Boston, and the Cantor Global Healthcare Conference on September 4 at 8:00 a.m. ET in New York. Both presentations will be available via webcast on the company's website for 30 days after the events.

BRISBANE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences:

• Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 3:00 p.m. ET in Boston, MA; and,
• Cantor Global Healthcare Conference on Thursday, September 4, 2025, at 8:00 a.m. ET in New York, NY.
  
  

Live webcasts of the presentations can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. Replays of the webcasts will be archived on the Annexon website for 30 days following the presentations.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neuroinflammation as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss in a host of diseases. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade before it starts. Our pipeline spans three diverse therapeutic areas – autoimmunity, neurodegeneration and ophthalmology – and includes targeted investigational drug candidates designed to address the unmet needs of nearly 10 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

Media Contact:
Beth Keshishian
917-912-7195
beth@bethkeshishian.com

FAQ

When and where will Annexon Biosciences (ANNX) present at the Wells Fargo Healthcare Conference 2025?

Annexon will present at the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 3:00 p.m. ET in Boston, MA.

When is Annexon's (ANNX) presentation at the Cantor Global Healthcare Conference 2025?

Annexon will present at the Cantor Global Healthcare Conference on Thursday, September 4, 2025, at 8:00 a.m. ET in New York, NY.

How can investors access Annexon Biosciences' (ANNX) conference presentations?

Investors can access live webcasts of the presentations through the 'Events & Presentations' section on the Investors page at www.annexonbio.com. Replays will be available for 30 days after the presentations.

What type of diseases does Annexon Biosciences (ANNX) focus on treating?

Annexon focuses on developing therapies for classical complement-mediated neuroinflammatory diseases affecting the body, brain, and eye.